Financial burden of prostate cancer in the Iranian population: a cost of illness and financial risk protection analysis

被引：0
作者：
Farbod Alinezhad
Farhad Khalili
Hossein Zare
Chunling Lu
Zahra Mahmoudi
Mahmood Yousefi
机构：
[1] Bouvé College of Health Sciences,Management Development, Resources and Planning
[2] Northeastern University,Department of Health Policy and Management
[3] Guilan University of Medical Sciences,Division of Global Health Equity
[4] Johns Hopkins Bloomberg School of Public Health,Department of Global Health & Social Medicine
[5] Brigham & Women’s Hospital,Department of Health Economics, School of Management and Medical Informatics
[6] Harvard Medical School,Tabriz Health Services Management Research Center, Department of Health Economics, School of Management and Medical Informatics
[7] Tabriz University of Medical Sciences,undefined
[8] Tabriz University of Medical Sciences.,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
Prostate cancer; Cost of illness; Prevalence-based; Health expenditures;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 122 条
[21]  
Gracey M(1995)Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies, by Frank Sloan. New York: Cambridge University Press, 1995, 273 pp., NPA J Policy Anal Manag 15 492-983
[22]  
King M(1958)Investment in human capital and personal income distribution J Polit Econ 66 281-e179
[23]  
Maher D(2020)Survival rate of prostate cancer in Asian countries: a systematic review and meta-analysis Ann Global Health 86 2-56
[24]  
Smeeth L(2018)A time preference measure of the social discount rate for Iran J Econ Struct 7 1-346
[25]  
Sekajugo J(2019)Private and social time preference for health outcomes: a general population survey in Iran PLoS ONE 14 e0211545-360
[26]  
Caldwell JC(2007)Protecting households from catastrophic health spending Health Aff 26 972-58
[27]  
Razi S(2021)Assessing the changes in Iranian household food basket using national household budget and expenditure survey data, 1991–2017 Int J Prev Med 6 e169-2913
[28]  
Rafiemanesh H(2018)Progress on catastrophic health spending in 133 countries: a retrospective observational study Lancet Global Health 105 49-885
[29]  
Ghoncheh M(2010)Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK BJU Int 105 338-371
[30]  
Khani Y(2010)Healthcare costs associated with prostate cancer: estimates from a population-based study BJU Int 12 355-undefined
12345678910